|February 2013 · Vol. 25, No. 2
Fertility drugs not linked to uterine cancer recurrence
Five-year disease-free survival similar for women who did or did not receive fertility drugs
For women who undergo fertility-sparing treatment for uterine cancer, subsequent use of fertility drugs is not associated with a higher incidence of cancer recurrence, according to research published in Obstetrics & Gynecology.
Jeong-Yeol Park, MD, PhD, from the University of Ulsan College of Medicine in Seoul, South Korea, and colleagues examined pregnancy outcomes based on a review of the medical records of 141 women with stage IA, grade 1 endometrioid adenocarcinoma of the uterus who had complete remission after fertility-sparing management using progestin.
Of the cohort, 38.3% had a history of infertility. After treatment, the median interval to attempted pregnancy was 5 months, and at the time of the pregnancy trial, the median age was 32.4 years. The researchers found that 60 women (49.6%) tried to conceive, of which 62.9% received fertility drugs. Of the women who tried to conceive, 73% were successful and 66% gave birth (46 women to 58 live neonates). The spontaneous abortion rate was 24%, ectopic pregnancy rate 2.8%, and preterm delivery rate 11.5%. Women who did versus did not receive fertility drugs had similar 5-year disease-free survival (73% versus 62%; P = 0.335), and for women who achieved at least one pregnancy, this rate was even higher compared with those who did not achieve pregnancy (76% versus 62%; P = 0.028).
“The use of fertility drugs was not associated with a higher incidence of cancer recurrence after successful fertility-sparing management in this study population,” the authors write.
To read the abstract of “Pregnancy Outcomes After Fertility-Sparing Management in Young Women With Early Endometrial Cancer” CLICK HERE.
Copyright © 2013 HealthDay. All rights reserved.We want to hear from you! Tell us what you think.
More NEWS FOR YOUR PRACTICE…